Új terápiás célpontok szisztémás lupus erythematosusban a patogenezis tükrében

Anna Bazsó, G. Poór, Péter Gergely, E. Kiss

Research output: Article

1 Citation (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder involving different organs and organ systems with consequent characteristic clinical and serologic symptoms. Despite of the improvement in lupus survival, approximately 10-20% of patients do not respond to traditional immune suppressive therapies. Relapses are more frequent; e.g. after cyclophosphamide therapy diffuse proliferative nephritis flares in 1/3 of patients. Different immune competent cells and inflammatory mediators participate in the pathogenesis of SLE involving both the adaptive and innate immunity. Several pathogenic elements and mechanisms may serve as therapeutic targets, consequently. Authors summarize novel therapeutic possibilities and their mechanisms regarding the pathogenesis of SLE. Immune modulation of B and T cells, co-stimulatory pathways, cytokine network, soluble mediators and autologous hemopoietic stem cell transplantation are discussed.

Original languageHungarian
Pages (from-to)735-740
Number of pages6
JournalOrvosi Hetilap
Volume151
Issue number18
DOIs
Publication statusPublished - máj. 1 2010

Fingerprint

Systemic Lupus Erythematosus
Nephritis
Stem Cell Transplantation
Adaptive Immunity
Therapeutics
Innate Immunity
Cyclophosphamide
B-Lymphocytes
Cytokines
T-Lymphocytes
Recurrence
Survival

Keywords

  • Biologic therapy
  • Pathogenesis
  • SLE
  • Stem cell transplantation
  • Targeted therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Új terápiás célpontok szisztémás lupus erythematosusban a patogenezis tükrében. / Bazsó, Anna; Poór, G.; Gergely, Péter; Kiss, E.

In: Orvosi Hetilap, Vol. 151, No. 18, 01.05.2010, p. 735-740.

Research output: Article

@article{969286566dc8400f8faf400526142599,
title = "{\'U}j ter{\'a}pi{\'a}s c{\'e}lpontok sziszt{\'e}m{\'a}s lupus erythematosusban a patogenezis t{\"u}kr{\'e}ben",
abstract = "Systemic lupus erythematosus (SLE) is an autoimmune disorder involving different organs and organ systems with consequent characteristic clinical and serologic symptoms. Despite of the improvement in lupus survival, approximately 10-20{\%} of patients do not respond to traditional immune suppressive therapies. Relapses are more frequent; e.g. after cyclophosphamide therapy diffuse proliferative nephritis flares in 1/3 of patients. Different immune competent cells and inflammatory mediators participate in the pathogenesis of SLE involving both the adaptive and innate immunity. Several pathogenic elements and mechanisms may serve as therapeutic targets, consequently. Authors summarize novel therapeutic possibilities and their mechanisms regarding the pathogenesis of SLE. Immune modulation of B and T cells, co-stimulatory pathways, cytokine network, soluble mediators and autologous hemopoietic stem cell transplantation are discussed.",
keywords = "Biologic therapy, Pathogenesis, SLE, Stem cell transplantation, Targeted therapy",
author = "Anna Bazs{\'o} and G. Po{\'o}r and P{\'e}ter Gergely and E. Kiss",
year = "2010",
month = "5",
day = "1",
doi = "10.1556/OH.2010.28863",
language = "Hungarian",
volume = "151",
pages = "735--740",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "18",

}

TY - JOUR

T1 - Új terápiás célpontok szisztémás lupus erythematosusban a patogenezis tükrében

AU - Bazsó, Anna

AU - Poór, G.

AU - Gergely, Péter

AU - Kiss, E.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Systemic lupus erythematosus (SLE) is an autoimmune disorder involving different organs and organ systems with consequent characteristic clinical and serologic symptoms. Despite of the improvement in lupus survival, approximately 10-20% of patients do not respond to traditional immune suppressive therapies. Relapses are more frequent; e.g. after cyclophosphamide therapy diffuse proliferative nephritis flares in 1/3 of patients. Different immune competent cells and inflammatory mediators participate in the pathogenesis of SLE involving both the adaptive and innate immunity. Several pathogenic elements and mechanisms may serve as therapeutic targets, consequently. Authors summarize novel therapeutic possibilities and their mechanisms regarding the pathogenesis of SLE. Immune modulation of B and T cells, co-stimulatory pathways, cytokine network, soluble mediators and autologous hemopoietic stem cell transplantation are discussed.

AB - Systemic lupus erythematosus (SLE) is an autoimmune disorder involving different organs and organ systems with consequent characteristic clinical and serologic symptoms. Despite of the improvement in lupus survival, approximately 10-20% of patients do not respond to traditional immune suppressive therapies. Relapses are more frequent; e.g. after cyclophosphamide therapy diffuse proliferative nephritis flares in 1/3 of patients. Different immune competent cells and inflammatory mediators participate in the pathogenesis of SLE involving both the adaptive and innate immunity. Several pathogenic elements and mechanisms may serve as therapeutic targets, consequently. Authors summarize novel therapeutic possibilities and their mechanisms regarding the pathogenesis of SLE. Immune modulation of B and T cells, co-stimulatory pathways, cytokine network, soluble mediators and autologous hemopoietic stem cell transplantation are discussed.

KW - Biologic therapy

KW - Pathogenesis

KW - SLE

KW - Stem cell transplantation

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77951624178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951624178&partnerID=8YFLogxK

U2 - 10.1556/OH.2010.28863

DO - 10.1556/OH.2010.28863

M3 - Article

C2 - 20410000

AN - SCOPUS:77951624178

VL - 151

SP - 735

EP - 740

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 18

ER -